Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.93 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091157 | 1.00 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL1091121 | 1.00 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL3015992 | 1.00 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL1091158 | 1.00 | TGM2 (0.93) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL1103744 | 0.96 | TGM2 (1.00) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL13934076 | 0.96 | TGM2 (1.00) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL14070443 | 0.94 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL9826132 | 0.94 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL4925942 | 0.94 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK | |
| SCHEMBL4950327 | 0.94 | TGM2 (0.86) | TGM2CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-11-24 | — | — | US | claimed |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; AND THE WASHINGTON UNIVERSITY | 2009-12-17 | — | — | US | claimed |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-02-12 | — | — | US | claimed |
| EP-1931205-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-06-18 | — | — | EP | claimed |
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-02-21 | — | — | US | claimed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | claimed |
| WO-2007025247-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-03-01 | — | — | WO | claimed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | claimed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | claimed |
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8470782-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-8153593-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-11-24 | — | — | US | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007025247-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | disclosed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | TGM2 13/4885CTSL 188/4885CTSB 127/4885 |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | TGM2, TGM3, TGM1 | TGM2 1/4885CTSL 226/4885CTSB 131/4885 |
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | TGM2, TGM3, TGM1 | TGM2 1/4885CTSL 226/4885CTSB 131/4885 |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | TGM2 13/4885CTSL 188/4885CTSB 127/4885 |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | MGMT, GMFG, HNMT | TGM2 5/4885CTSL 400/4885CTSB 420/4885 |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | SI, DNPEP, SPINT2 | TGM2 13/4885CTSL 188/4885CTSB 127/4885 |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | TGM2, TGM3, TGM1 | TGM2 1/4885CTSL 226/4885CTSB 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.